Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in China
GLP-1 RA or GIP/GLP-1RA are not cost-effective for obesity treatment in China currently. Nevertheless, semaglutide exhibits relatively favourable economic potential across multiple subgroups.
Authors
- Liushi Zheng
- Maobai Liu (ORCID: https://orcid.org/0000-0002-8382-7868)
- Jiahao Zhang (ORCID: https://orcid.org/0000-0001-6433-4817)
- Na Li (ORCID: https://orcid.org/0000-0002-5529-0127)
- Bin Zheng (ORCID: https://orcid.org/0000-0001-8429-5384)
- Libin Liu (ORCID: https://orcid.org/0000-0002-0352-3865)
- Jingwen Lin
- Jianying Lei (ORCID: https://orcid.org/0009-0005-0178-9853)
- Wu Fu
- Caicong You
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1111/dom.16581
- Citations
- 4
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- National Natural Science Foundation of China
- National Health Commission of the People's Republic of China